Health Ministry proposes GSDP rules, eases Schedule M norms for 3 drug categories

Share:
Audio Loading voice…
Health Ministry proposes GSDP rules, eases Schedule M norms for 3 drug categories

Synopsis

India's Health Ministry has simultaneously proposed two pharma regulatory changes: a binding GSDP framework to protect drug quality across the entire distribution chain, and targeted Schedule M relaxations for medicinal gases, gelatin capsules, and disinfectant fluids — categories the DTAB found were being held to inapplicable manufacturing standards. Both draft notifications are open for stakeholder comment.

Key Takeaways

The Union Ministry of Health and Family Welfare issued two draft Gazette notifications on 6 November 2026 proposing changes to the Drugs Rules, 1945 .
The proposed GSDP framework , developed by CDSCO , covers procurement, storage, transportation, and documentation across the pharmaceutical distribution chain.
Regulatory flexibility under the revised Schedule M has been proposed for medicinal gases , empty gelatin capsules , and disinfectant fluids .
The Drugs Technical Advisory Board (DTAB) recommended the Schedule M carve-out at its 93rd meeting on 16 February 2026 .
Both notifications are draft proposals; final rules will be issued after stakeholder feedback.

The Union Ministry of Health and Family Welfare on Thursday, 19 November 2026, proposed amendments to the Drugs Rules, 1945, introducing a formal Good Storage and Distribution Practices (GSDP) framework and easing certain revised Schedule M requirements for three specific drug product categories. The dual-track reform is aimed at both tightening quality controls across India's pharmaceutical supply chain and addressing practical manufacturing concerns raised by industry stakeholders.

What the GSDP Framework Proposes

The proposed GSDP guidelines, developed on the basis of recommendations by the Central Drugs Standard Control Organisation (CDSCO), are designed to ensure that the quality, safety, efficacy, and integrity of pharmaceutical products are preserved at every link in the distribution chain — from manufacturers and importers to end patients. The draft notification covers procurement, purchasing, storage, transportation, documentation, and record-keeping, bringing Indian norms closer to international regulatory standards.

Notably, the GSDP framework would apply uniformly across all actors in the pharmaceutical distribution ecosystem, a significant structural step given the fragmented nature of drug logistics in India. The ministry issued the draft through Gazette Notification G.S.R. 985 (E), dated 6 November, published in the Gazette of India, inviting public comment ahead of finalisation.

Schedule M Relaxations for Three Product Categories

In a separate but simultaneous draft notification issued on 6 November, the ministry proposed regulatory flexibility under the revised Schedule M for medicinal gases, empty gelatin capsules, and disinfectant fluids. The move follows representations from industry stakeholders who flagged that certain manufacturing requirements under the revised Schedule M were not applicable — or were technically incompatible — with the production processes of these categories.

The Drugs Technical Advisory Board (DTAB) examined the matter at its 93rd meeting held on 16 February 2026 and observed that some Schedule M provisions were not relevant to the manufacturing processes of these specific product segments, lending technical backing to the proposed carve-out.

Why This Matters for India's Pharma Sector

India is the world's largest supplier of generic medicines by volume, supplying roughly 20% of global generic drug exports. Any regulatory tightening or recalibration of domestic manufacturing and distribution norms carries direct implications for both domestic patients and export markets. Critics and patient advocacy groups have long argued that distribution-chain lapses — including improper storage and cold-chain failures — contribute to substandard drug quality reaching end consumers.

This comes amid heightened regulatory scrutiny of Indian pharmaceutical manufacturers following a series of international quality alerts in recent years. The GSDP proposal, if notified, would create a legally enforceable quality standard for the distribution segment, which has historically operated under softer guidelines.

What Happens Next

Both draft notifications are open for stakeholder feedback before being finalised. Industry bodies, drug manufacturers, and distributors are expected to submit representations, particularly on the GSDP compliance timelines and the precise scope of the Schedule M exemptions. Once the feedback period closes, the ministry is expected to issue the final Gazette notifications incorporating any revisions.

Point of View

However, is the simultaneous Schedule M relaxation: it reveals the tension between stricter manufacturing norms and the operational realities of niche product categories such as medicinal gases. If the DTAB's pragmatism on Schedule M becomes a template for other industry representations, there is a risk that carve-outs gradually erode the revised Schedule M's core rigour. The ministry will need to draw a clear line between science-based exemptions and industry convenience.
NationPress
19 Nov 2026

Frequently Asked Questions

What is the GSDP framework proposed by India's Health Ministry?
The Good Storage and Distribution Practices (GSDP) framework is a proposed regulatory standard under the Drugs Rules, 1945, designed to ensure pharmaceutical product quality, safety, and efficacy are maintained throughout the distribution chain — from manufacturers and importers to patients. It covers procurement, storage, transportation, documentation, and record-keeping, based on CDSCO recommendations.
Which drug categories are getting Schedule M relaxations and why?
Medicinal gases, empty gelatin capsules, and disinfectant fluids are the three categories proposed for regulatory flexibility under the revised Schedule M. The Drugs Technical Advisory Board (DTAB) observed at its 93rd meeting on 16 February 2026 that certain Schedule M manufacturing provisions were not applicable to the production processes of these categories, prompting the targeted exemption.
What is the revised Schedule M?
Schedule M is a part of the Drugs Rules, 1945, that lays down Good Manufacturing Practices (GMP) for pharmaceutical manufacturers in India. The revised Schedule M introduced updated and more stringent quality standards; the latest draft notifications propose limited relaxations for specific product categories that the DTAB found incompatible with certain provisions.
When will the new drug distribution rules come into effect?
Both proposals are currently in draft form, issued via Gazette Notification G.S.R. 985 (E) dated 6 November. They are open for stakeholder feedback before finalisation. The ministry has not announced a specific implementation timeline; final Gazette notifications are expected after the comment period closes.
Why is a GSDP framework important for India's pharmaceutical sector?
India is one of the world's largest exporters of generic medicines, and gaps in distribution-chain quality controls have been linked to substandard drugs reaching consumers. A legally enforceable GSDP standard would close a regulatory gap that has historically allowed distribution-stage quality lapses to go unchecked, strengthening both domestic patient safety and India's credibility in international export markets.
Nation Press
The Trail

Connected Dots

Tracing the thread behind this story — newest first.

8 Dots
  1. Latest 2 weeks ago
  2. 1 month ago
  3. 2 months ago
  4. 3 months ago
  5. 4 months ago
  6. 4 months ago
  7. 1 year ago
  8. 1 year ago
Google Prefer NP
On Google